Topical steroid risk analysis: Differentiating between physiologic and pathologic adrenal suppression

References

• Fraser CG, Preuss FS, Bigford WD. Adrenal atrophy and irreversible shock associated with cortisone therapy. J Am Med Assoc. 1952;149:1542–3. PubMed PMID: 14945970. Epub 1952/08/23. eng
   PubMed Web of Science ®Google Scholar
• Lewis L, Robinson RF, Yee J, et al. Fatal adrenal cortical insufficiency precipitated by surgery during prolonged continuous cortisone treatment. Ann Intern Med. 1953;39:116–26. PubMed PMID: 13065993. Epub 1953/07/01. eng
   PubMed Web of Science ®Google Scholar
• Schimmer BP, Parker KL. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. In Brunton LL, Lazo JS, Parker KL, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 11th ed. New York: McGraw-Hill, 2006. p 1587--612
   Google Scholar
• Turpeinen M, Salo OP, Leisti S. Effect of percutaneous absorption of hydrocortisone on adrenocortical responsiveness in infants with severe skin disease. Br J Dermatol. 1986;115:475–84. PubMed PMID: 2946314. Epub 1986/10/01. eng
   PubMed Web of Science ®Google Scholar
• Haeck IM, Timmer-de Mik L, Lentjes EG, et al. Low basal serum cortisol in patients with severe atopic dermatitis: potent topical corticosteroids wrongfully accused. Br J Dermatol. 2007;156:979–85. PubMed PMID: 17298484. Epub 2007/02/15. eng
   Google Scholar
• Katz HI, Hien NT, Prawer SE, et al. Superpotent topical steroid treatment of psoriasis vulgaris – clinical efficacy and adrenal function. J Am Acad Dermatol. 1987;16:804–11. PubMed PMID: 3553247. Epub 1987/04/01. eng
   PubMed Web of Science ®Google Scholar
• Galderma Laboratories L. An open label, on-comparative evaluation of the adrenal suppression potential of clobetasol propionate 0.05% spray in subjects with moderate to severe plaque psoriasis: two and four week treatment. Study report D02-0204-03. Data on file. 2004
   Google Scholar
• Eriksen K. Comparison of clobetasol propionate and betamethasone-17,21-dipropionate with reference to adrenal suppression. Acta Derm Venereol. 1979;59:372–4. PubMed PMID: 92159. Epub 1979/01/01. eng
   Google Scholar
• Gammon W, Krueger G, Van Scott E. Intermittent short courses of clobetasol propionate ointment 0.05% in the treatment of psoriasis. Curr Ther Res. 1987;42:419–27
   Google Scholar
• Olsen EA, Cram DL, Ellis CN, et al. A double-blind, vehicle-controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis. J Am Acad Dermatol. 1991;24:443–7. PubMed PMID: 2061442. Epub 1991/03/01. eng
   PubMed Web of Science ®Google Scholar
• Melian EB, Spencer CM, Jarvis B. Clobetasol propionate foam, 0.05%. Am J Clin Dermatol. 2001;2:89–92; discussion 3. PubMed PMID: 11705308. Epub 2001/11/14. eng
   PubMedGoogle Scholar
• Plemons JM, Rees TD, Zachariah NY. Absorption of a topical steroid and evaluation of adrenal suppression in patients with erosive lichen planus. Oral Surg Oral Med Oral Pathol. 1990;69:688–93. PubMed PMID: 2356081. Epub 1990/06/01. eng
   PubMedGoogle Scholar
• Delescluse J, van der Endt JD. A comparison of the safety, tolerability, and efficacy of fluticasone propionate ointment, 0.005%, and betamethasone-17,21-dipropionate ointment, 0.05%, in the treatment of eczema. Cutis. 1996;57:32–8. PubMed PMID: 8646867. Epub 1996/02/01. eng
   Google Scholar
• Cornell RC, Stoughton RB. Six-month controlled study of effect of desoximetasone and betamethasone 17-valerate on the pituitary-adrenal axis. Br J Dermatol. 1981;105:91–5. PubMed PMID: 7259982. Epub 1981/07/01. eng
   PubMed Web of Science ®Google Scholar
• Kelly JW, Cains GD, Rallings M, Gilmore SJ. Safety and efficacy of mometasone furoate cream in the treatment of steroid responsive dermatoses. Australas J Dermatol. 1991;32:85–91. PubMed PMID: 1781761. Epub 1991/01/01. eng
   Google Scholar
• Tomasini C, Castiglioni G. Plasma cortisol studies with 0.05% halometasone cream and ointment in patients with psoriasis. J Int Med Res. 1983;11:38–42. PubMed PMID: 6832467. Epub 1983/01/01. eng
   Google Scholar
• Franz TJ, Parsell DA, Halualani RM, et al. Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy. Int J Dermatol. 1999;38:628–32. PubMed PMID: 10487457. Epub 1999/09/16. eng
   PubMed Web of Science ®Google Scholar
• Hebert AA, Friedlander SF, Allen DB. Topical fluticasone propionate lotion does not cause HPA axis suppression. J Pediatr. 2006;149:378–82. PubMed PMID: 16939752. Epub 2006/08/31. eng
   Google Scholar
• Lucky AW, Grote GD, Williams JL, et al. Effect of desonide ointment, 0.05%, on the hypothalamic-pituitary-adrenal axis of children with atopic dermatitis. Cutis. 1997;59:151–3. PubMed PMID: 9071556. Epub 1997/03/01. eng
   PubMed Web of Science ®Google Scholar
• Dohil MA, Alvarez-Connelly E, Eichenfield LF. Fluocinolone acetonide 0.01% in peanut oil: safety and efficacy data in the treatment of childhood atopic dermatitis in infants as young as 3 months of age. Pediatr Dermatol. 2009;26:262–8. PubMed PMID: 19706085. Epub 2009/08/27. eng
   Google Scholar
• Carruthers JA, August PJ, Staughton RC. Observations on the systemic effect of topical clobetasol propionate (Dermovate). Br Med J. 1975;4:203–4. PubMed PMID: 1191997. Pubmed Central PMCID: 1674965. Epub 1975/10/25. eng
   PubMedGoogle Scholar
• Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60:643–59. PubMed PMID: 19217694. Epub 2009/02/17. eng
   PubMed Web of Science ®Google Scholar
• Munro DD. Topical corticosteroid therapy and its effect on the hypothalamic-pituitary-adrenal axis. Dermatologica. 1976;152:173–80. PubMed PMID: 782954. Epub 1976/01/01. eng
   Google Scholar
• Kelly A, Nelson K, Goodwin M, McCluggage J. Iatrogenic Cushing's syndrome. Br Med J. 1972;4:114. PubMed PMID: 5077452. Pubmed Central PMCID: 1786266. Epub 1972/10/14. eng
   Google Scholar
• Staughton RC, August PJ. Cushing's syndrome and pituitary-adrenal suppression due to clobetasol propionate. Br Med J. 1975;2:419–21. PubMed PMID: 1125562. Pubmed Central PMCID: 1681806. Epub 1975/05/24. eng
   PubMed Web of Science ®Google Scholar
• Himathongkam T, Dasanabhairochana P, Pitchayayothin N, Sriphrapradang A. Florid Cushing's syndrome and hirsutism induced by desoximetasone. JAMA. 1978;239:430–1. PubMed PMID: 621843. Epub 1978/01/30. eng
   Google Scholar
• Nathan AW, Rose GL. Fatal iatrogenic Cushing's syndrome. Lancet. 1979;1:207. PubMed PMID: 84219. Epub 1979/01/27. eng
   Google Scholar
• Cook LJ, Freinkel RK, Zugerman C, et al. Iatrogenic hyperadrenocorticism during topical steroid therapy: assessment of systemic effects by metabolic criteria. J Am Acad Dermatol. 1982;6:1054–60. PubMed PMID: 7047591. Epub 1982/06/01. eng
   PubMed Web of Science ®Google Scholar
• Fairris GM, White JE, Tymms DJ, Leatherdale BA. Cushing's syndrome, topical steroids, and cling film. Lancet. 1986;2:228. PubMed PMID: 2873479. Epub 1986/07/26. eng
   Google Scholar
• Sandoval Cruz M, Moncada B. Potent topical steroids and psoriasis. J Am Acad Dermatol. 1988;18:387. PubMed PMID: 3346427. Epub 1988/02/01. eng
   Google Scholar
• Young CA, Williams IR, MacFarlane IA. Unrecognised Cushing's syndrome and adrenal suppression due to topical clobetasol propionate. Br J Clin Pract. 1991;45:61–2. PubMed PMID: 1931550. Epub 1991/01/01. eng
   Google Scholar
• Ohnishi T, Suzuki T, Watanabe S, Takahashi H. Erythrodermic psoriasis associated with hyperuricemia and Iatrogenic Cushing's syndrome due to topical corticosteroid therapy. Int J Dermatol. 1996;35:379–80. PubMed PMID: 8734668. Epub 1996/05/01. eng
   PubMed Web of Science ®Google Scholar
• Gilbertson EO, Spellman MC, Piacquadio DJ, Mulford MI. Super potent topical corticosteroid use associated with adrenal suppression: clinical considerations. J Am Acad Dermatol. 1998;38:318–21. PubMed PMID: 9486706. Epub 1998/03/05. eng
   PubMed Web of Science ®Google Scholar
• Abma EM, Blanken R, De Heide LJ. Cushing's syndrome caused by topical steroid therapy for psoriasis. Neth J Med. 2002;60:148–50. PubMed PMID: 12164372. Epub 2002/08/08. eng
   PubMed Web of Science ®Google Scholar
• Castanedo-Cazares JP, Lopez-Lucio RH, Moncada B. Cushing syndrome following the prescription of antifungal, antibiotic, corticosteroid cream. Int J Dermatol. 2003;42:318. PubMed PMID: 12694505. Epub 2003/04/16. eng
   Google Scholar
• Gen R, Akbay E, Sezer K. Cushing syndrome caused by topical corticosteroid: a case report. Am J Med Sci. 2007;333:173–4. PubMed PMID: 17496736. Epub 2007/05/15. eng
   Google Scholar
• Daly J, Feiner A, Kroshinsky D. Cushing's syndrome caused by a “skin lightening” ointment purchased at a Brooklyn neighborhood beauty store. J Am Acad Dermatol. 2008;58:AB98
   Google Scholar
• Pramick M, Whitmore SE. Cushing's syndrome caused by mucosal corticosteroid therapy. Int J Dermatol. 2009;48:100–1. PubMed PMID: 19126065. Epub 2009/01/08. eng
   Google Scholar
• Durmazlar SP, Oktay B, Eren C, Eskioglu F. Cushing's syndrome caused by short-term topical glucocorticoid use for erythrodermic psoriasis and development of adrenal insufficiency after glucocorticoid withdrawal. Eur J Dermatol. 2009;19:169–70. PubMed PMID: 19106046. Epub 2008/12/25. eng
   Google Scholar
• Tempark T, Phatarakijnirund V, Chatproedprai S, et al. Exogenous Cushing's syndrome due to topical corticosteroid application: case report and review literature. Endocrine. 2010;38:328–34. PubMed PMID: 20972726. Epub 2010/10/26. eng
   PubMed Web of Science ®Google Scholar
• Graber AL, Ney RL, Nicholson WE, et al. Natural history of pituitary-adrenal recovery following long-term suppression with corticosteroids. J Clin Endocrinol Metab. 1965;25:11–6. PubMed PMID: 14252277. Epub 1965/01/01. eng
   PubMed Web of Science ®Google Scholar
• Helfer EL, Rose LI. Corticosteroids and adrenal suppression. Characterising and avoiding the problem. Drugs. 1989;38:838–45. PubMed PMID: 2689140. Epub 1989/11/01. eng
   Google Scholar
• Feldmann RJ, Maibach HI. Regional variation in percutaneous penetration of 14C cortisol in man. J Invest Dermatol. 1967;48:181–3. PubMed PMID: 6020682. Epub 1967/02/01. eng
   PubMed Web of Science ®Google Scholar
• Wester R, Maibach H. Dermatopharmacokinetics in clinical dermatology. Semin Dermatol. 1983;2:81–4
   Google Scholar
• Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54:1–15; quiz 6-8. PubMed PMID: 16384751. Epub 2005/12/31. eng
   PubMed Web of Science ®Google Scholar
• Goa KL. Clinical pharmacology and pharmacokinetic properties of topically applied corticosteroids. A review. Drugs. 1988;36:51–61. PubMed PMID: 3076132. Epub 1988/01/01. eng
   PubMedGoogle Scholar
• Ozon A, Cetinkaya S, Alikasifoglu A, et al. Inappropriate use of potent topical glucocorticoids in infants. J Pediatr Endocrinol Metab. 2007;20:219–25. PubMed PMID: 17396439. Epub 2007/04/03. eng
   PubMed Web of Science ®Google Scholar
• Levin C, Maibach HI. Topical corticosteroid-induced adrenocortical insufficiency: clinical implications. Am J Clin Dermatol. 2002;3:141–7. PubMed PMID: 11978135. Epub 2002/04/30. eng
   PubMedGoogle Scholar
• Bhutani T, Zitelli KB, Koo J. Yin-yang strategy: proposing a new, effective, repeatable, sequential therapy for psoriasis. J Drugs Dermatol. 2011;10:831–4. PubMed PMID: 21818503. Epub 2011/08/06. eng
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Yoles A, Lombardi K, Lou W. Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: effects on the duration of improvement. J Am Acad Dermatol. 1998;39:447–50. PubMed PMID: 9738781. Epub 1998/09/17. eng
   PubMed Web of Science ®Google Scholar